Seeking men and women 18 years of age or older with primary progressive multiple sclerosis for participation in a study of an investigational drug called Ocrelizumab
We are studying the effects if a drug named ocrelizumab at higher doses than currently approved for patients with primary progressive multiple sclerosis (PPMS).
What we're hoping for
To evaluate the safety and efficacy of higher doses of ocrelizumab in patients with primary progressive multiple sclerosis (PPMS) and whether a higher dose can slow down the progression and worsening of PPMS.
ClinicalTrials.gov Identifier: NCT04548999